Subscribe

Background: In an era of multiple effective treatment options for relapsed/refractory multiple myeloma (MM), a recent meta-analysis has shown that retreatment with bortezomib continues to be an effective option in previously treated patients who relapsed. As economic pressures rise in oncology, it is important to evaluate the cost-effectiveness of newer therapies relative to standards of care. Carfilzomib was recently approved by the US Food and Drug Administration for the treatment of relapsed/refractory MM.

Background: Treatment of patients with RRMM can be challenging because of debilitating PN caused by the disease itself or by MM treatments. Neuropathy at diagnosis is prevalent (20–54%, depending on evaluation type [Richardson PA, et al. J Clin Oncol. 2009]) and can commonly be exacerbated by MM treatments (eg, bortezomib- or thalidomide-induced PN; BIPN or TIPN). PN reduces quality of life and leads to increased PN-related healthcare expenditures (eg, diagnostic testing and pharmaceutical and non-pharmaceutical interventions [Snowdon JA, et al.

Background: While broadly utilized for treatment of anemia in cancer patients, treatment with erythropoietin stimulating agents (ESA) is not recommended in patients who fail to respond within 6-8 weeks.

Objective: This study examined the rate of adverse events (AE) and costs of continued exposure to ESAs in the absence of clinical response compared to those responding to ESA treatment.

Abstracts to Be Presented at the
 Third Annual Conference of the Association for Value-Based Cancer Care

May 2-5, 2013
Westin Diplomat, Hollywood, FL

 

Category: Cost-Effectiveness Analysis

Multiple myeloma (MM) is characterized by the clonal expansion of malignant plasma cells that proliferate in the bone marrow, which typically produce large amounts of an abnormal immunoglobulin-like protein.1,2 The etiology of MM is unknown, but is associ­ated with exposure to particular chemicals or to radiation and with being overweight or obese.3,4 MM is often preceded by monoclonal gammopathy of undetermined significance, an asymptomatic plasma-cell disorder, which may progress through asymptomatic smoldering MM before becoming symptomatic MM.2,5

The US Food and Drug Admini­stration (FDA) accelerated the approval of pomalidomide (Pomalyst capsules; Celgene) for the treatment of patients with multiple myeloma who have received at least 2 previous myeloma therapies, including lenalidomide (Revlimid) and bortezomib (Velcade), and whose disease progressed while receiving these therapies or within 60 days of stopping the last therapy.

On February 8, 2013, the US Food and Drug Administration (FDA) accelerated the approval of pomalidomide (Pomalyst capsules; Celgene) for the treatment of patients with multiple myeloma who have received at least 2 previous myeloma therapies, including lenalidomide (Revlimid) and bortezomib (Velcade), but whose disease progressed while receiving these therapies or within 60 days of stopping the last therapy. 

At the 2012 American Society of Hematology annual meeting, Gareth Morgan, MD, PhD, Professor of Hematology at the Centre for Myeloma Research, The Institute of Cancer Research, and The Royal Marsden Hospital in London, United Kingdom, discussed the growing appreciation of the molecular foundation of multiple myeloma at the molecular level and predicted how the “new biology” will change treatment in the clinic.

The novel agent ARRY-520 showed promising activity in a relapsed/refractory population—most of them heavily pretreated and refractory to lenalidomide, bortezomib, and dexamethasone—without producing peripheral neuropathy, according to Jatin Shah, MD, from the University of Texas M.D. Anderson Cancer Center in Houston. Dr Shah described the new drug at the 2012 American Society of Hematology annual meeting.

Atlanta, GA—MLN9708, an investigational, second-generation oral proteasome inhibitor (which is in the same class of drugs as bortezomib), produced impressive results in a phase 1/2 clinical trial of treatment-naïve patients with multiple myeloma that was featured in a press briefing at the 2012 Annual Meeting of the American Society of Hematology.

Page 10 of 21
Results 91 - 100 of 209
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology